After many years trading as Biotechinforma .com we have decided to change our web address to www.biotechinpharma.com, which will soon be going live. We have decided the new web address more accurately reflects our commitment to assisting Biotech Companies and suppliers involved in Biopharma and Pharmaceutical industry liaisons.

Biotech Inpharma is the news portal and database where industry and suppliers meet...

The Biotech Database lists in detail over 10,000 Biotech companies and resource suppliers characterised by speciality and geographical location, these include listings for biotech companies, biotech suppliers, biotech finance and biotech R&D companies.


Biotech Informa is a unique database of Biotech companies, the Biotech database covers everything from biotech companies and biotech suppliers to biotech finance and biotech R&D companies.

Our news service brings you up to the minute information about developments in the Biotech Industry including new products, clinical data, mergers and acquisitions as well as changes in regulations etc.

We keep you up to date with a worldwide list of key Biotechnology conferences, courses and meetings. We give you the opportunity to showcase your products and services to your target audience.

The Biotech databases unique feature is the ablility, once you are registered, to make your own entry and change it whenever required from your computer so the information is always up to date.

This is the web portal the Biotech Industry and all who wish to provide resources has been needing.

BIOTECH INPHARMA is a unique database of biotech companies and their suppliers plus up-to-date biotech news of finance and technology.

BIOTECH COMPANIES





Categories at a glance:

Academia & institutions Drug discovery
Agriculture & feedstocks Genes & proteins
Biofuels & energy Human therapeutics
Bioprocessing Medical devices
Biotech R & D Nanotechnology
Diagnostics Nutraceuticals
Drug delivery OTC
Drug development Pharmaceuticals

BIOTECH SUPPLIERS





Categories at a glance:

Advertising IT services
Bioengineering Lab equipment
Biotech consultancies Lab instrumentation
Business services Legal / IP
Communication/education Logistics & distribution
Consultancies Marketing & sales
CROs Medical Devices
Decontamination Packaging & printing
Event management Publishing
Education & training R & D
Finance & investment Recruitment
Gene Services Regulatory affairs
Information services Research models & services
Insurance services Translation
IT services

BIOTECH NEWS

Biotech Ascletis announce Specialty Therapeutics Venture SciClone Acquires China based NovaMed Pharmaceuticals

Ascletis, Inc., a U.S.-China specialty life sciences venture focused on cancer and infectious disease therapeutics, have announced the company’s formation and completion of a Series A private equity financing. Ascletis has raised US$100 million in committed financing including a first tranche of US$50 million. The investors, led by Hangzhou Binjiang Investment Holding Co., Ltd., included private entrepreneurs from China and other countries including the United States. Ascletis is led by co-founder, President and Chief Executive Officer, Jinzi J. Wu, Ph.D., who was previously Vice President, Global HIV Drug Discovery at GlaxoSmithKline. “We are very pleased to complete this significant investment that provides a strong financial base and committed long-term support from a group of experienced private investors,” said Dr. Wu. “We believe that the formation and funding of Ascletis represents the first large-scale investment by Chinese entrepreneurs in U.S. pharmaceutical/biotech innovation.”

SciClone Pharmaceuticals, Inc. have announced that it has acquired NovaMed Pharmaceuticals Inc., a China-based specialty pharmaceutical company. The acquisition brings additional broad sales and marketing, as well as regulatory and extensive business capabilities and pharmaceutical assets in the regulatory approval stage to its growing and profitable China-focused specialty pharmaceutical business. SciClone believes this acquisition will further position it as a leader in the rapidly expanding pharmaceutical industry in China. "NovaMed represents an excellent strategic acquisition as it allows SciClone, in a single transaction, to dramatically expand our presence in China in five important areas: pharmaceutical products, targeted therapeutic indications, management depth, sales force size and revenue," stated Friedhelm Blobel, Ph.D., President and Chief Executive Officer of SciClone. "Whereas SciClone had already established itself in China with our successful ZADAXIN® franchise, we have now evolved into a formidable presence in this fast growing market with a combined sales force of more than 680 individuals, nearly 20 commercial stage products spanning several key indications, and an expanded Shanghai based management team with significant pharmaceutical industry experience."

 
Merck to Acquire Inspire Pharmaceuticals, Inc evocatal & EUCODIS Bioscience form new Alliance
Merck and Inspire Pharmaceuticals, Inc. have announced that they have entered into a definitive agreement under which Merck will acquire Inspire, a specialty pharmaceutical company focused on developing and commercializing ophthalmic products. Under the terms of the agreement, Merck, through a subsidiary, will commence a tender offer for all outstanding common stock of Inspire at a price of $5.00 per share in cash, a 26 percent premium to the closing price of Inspire's common stock on April 4, 2011. The transaction has a total cash value of approximately $430 million. The transaction has been unanimously approved by the boards of directors of both companies and Inspire's board recommended that the company's shareholders tender their shares pursuant to the tender offer. In addition, Warburg Pincus Private Equity IX, L.P., which owns approximately 28 percent of the outstanding shares of Inspire, has agreed to tender all of its shares into the offer.

Industrial biotech companies EUCODIS Bioscience and evocatal have announced the formation of an alliance to jointly market the companies’ industrial enzyme products, including alcohol dehydrogenases, lipases, and other enzymes. The two companies will leverage their knowledge of customers’ needs in their respective markets as well as their complementary resources to provide existing and future customers with a broader choice of novel enzymes and related services. Both parties have already started to align their marketing and sales activities, including their product catalogs, and are representing and marketing each partner’s products at industry trade fairs, beginning with CPhI 2010, Paris, and Biotechnica 2010, Hannover.

 
Eli Lilly to invest $250M in Australian Biotech industry Novozymes and Ceres partner on biofuel crops

Eli Lilly and Company, and other strategic US partners will create an investment fund of up to USD$250 million to back the expansion and development of the Queensland and Australian biotechnology industry. The Queensland Government is investing $25 million in the venture capital fund. Lilly will contribute up to 20 percent of the total funding, while other strategic investors will also participate. “Today represents a turning point in support for home-grown ideas and innovation,” said Premier Anna Bligh. “We have just secured a major venture capital fund with several prominent names in the US to provide the financial muscle needed to bring Queensland ideas and innovation to the commercial stage right at home in our own backyard. We have a plan to make Queensland's biotechnology industry worth $20 billion and employ 16,000 people by 2025."

Energy crop company Ceres, Inc. and Novozymes, the world’s largest enzyme provider, have entered a research collaboration to co-develop customized plant varieties and enzyme cocktails for the production of cellulosic biofuel.  The companies expect to improve the process of converting biomass to fuel through more effective enzymes and higher quality energy crops in a joint optimization project that will lead to greater fuel yields, as well as lower capital and operating costs. “This is an example of how technology providers from different parts of the value chain are coming together to make cellulosic biofuel a commercial reality. Energy crops have an important role to play in the world’s future, sustainable energy mix.  According to the Billion Ton Study by the US Department of Energy, one third of the total sustainably collected biomass potential from agricultural resources can come from perennial crops,” said Cynthia Bryant, Global Biomass Business Development Manager of Novozymes.

 

  • Our news service brings you up to the minute information about developments in the Biotech Industry including new products, clinical data, mergers and acquisitions as well as changes in regulations etc.
  • We keep you up to date with a worldwide list of key Biotechnology conferences, courses and meetings.
  • We give you the opportunity to showcase your products and services to your target audience.
  • Our unique feature is the ablility, once you are registered, to make your own entry and change it whenever required from your computer so the information is always up to date.
  • This is the web portal the Biotech Industry and all who wish to provide resources has been needing.

Back to top